National Health (Pharmaceutical Benefits) Regulations (Amendment)

Overview

The National Health Act 1953 was enacted to provide a framework for the regulation of health services in Australia, including the provision of pharmaceutical benefits. These regulations, made under the authority of the Act, aim to address the gap in the prescription of certain drugs and medicinal preparations as pharmaceutical benefits. Enacted by the Governor-General of the Commonwealth of Australia on the advice of the Federal Executive Council, these regulations amend the existing National Health (Pharmaceutical Benefits) Regulations to include new drugs and preparations recommended by the Pharmaceutical Benefits Advisory Committee. The policy objective is to expand the scope of pharmaceutical benefits available to the public, ensuring that more treatments are accessible under the National Health scheme. This legislative instrument seeks to enhance public health by updating the list of approved drugs and medicinal preparations that can be prescribed as pharmaceutical benefits.

Scope and Application

The National Health (Pharmaceutical Benefits) Regulations, as amended by Statutory Rules 1976 No. 150, apply to the inclusion of specific drugs and medicinal preparations into the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953. These regulations were enacted based on recommendations from the Pharmaceutical Benefits Advisory Committee, and they specify particular drugs and preparations that are to be added to the PBS. The regulations affect pharmaceutical entities and health practitioners within the Commonwealth of Australia by determining which medications are eligible for government subsidy, thus influencing the availability and affordability of these drugs to consumers. The amendments outlined in these regulations extend to a variety of drugs, including those for Parkinson's disease, infections, and various other medical conditions. While the primary focus is on expanding access to essential medications, the regulations also include certain conditions and restrictions on the use of specific drugs, requiring written authority from the Director-General for treatments such as corticosteroid therapy and certain infections. The regulations come into operation on 1 August 1976 and are applicable across the entire nation, thereby affecting all states and territories uniformly.

Key Provisions

The Regulations under the National Health Act 1953 amend the National Health (Pharmaceutical Benefits) Regulations by adding and omitting certain drugs and medicinal preparations from various schedules. These amendments were made based on recommendations from the Pharmaceutical Benefits Advisory Committee to the Minister. Specifically, Regulation 2 amends the First Schedule to add Senna Tablets and Sulphadimethoxine Tablets, Regulation 3 amends the Second Schedule to add Carbidopa Levodopa, B.P., with Carbidopa and Levodopa, B.P. Carbidopa with Levodopa, B.P., and Regulation 4 amends the Third Schedule to add Carbidopa, Prochlorperazine Edisylate, and Tobramycin Sulphate. Furthermore, Regulation 5 amends the Fifth Schedule to substitute or add new items such as Calciferol, B.P., Codeine Phosphate with Aspirin and Paracetamol Soluble Tablets, Levodopa, B.P., with Carbidopa, Tetracosactrin Acetate, B.P., Tetracosactrin Zinc Injection, B.P., and Tobramycin Sulphate, with specific conditions for their prescription as pharmaceutical benefits. These Regulations impose obligations on various parties, including the Pharmaceutical Benefits Advisory Committee, which is responsible for recommending drugs and medicinal preparations for inclusion as pharmaceutical benefits. The Minister, in turn, must consider these recommendations and, if approved, implement them through amendments to the Regulations. Additionally, the Director-General must provide written authority for certain drugs to be prescribed under specific conditions, ensuring that the use of these drugs is appropriate and controlled. The amendments also affect pharmacists and medical practitioners who must adhere to the updated schedules when dispensing or prescribing pharmaceutical benefits. The Regulations do not explicitly outline offences, penalties, or civil/criminal consequences for breaches. However, non-compliance with the National Health Act 1953 or its Regulations could result in administrative actions, fines, or other penalties as prescribed by the Act. For instance, unauthorised prescribing or dispensing of pharmaceutical benefits not listed in the schedules could lead to disciplinary actions against medical practitioners or pharmacists, including suspension or revocation of their registration. Similarly, failure to adhere to the conditions specified for certain drugs could result in penalties imposed by the relevant authorities.